Document:

exv4wd

EXHIBIT
(4)(d)

AMERICAN GENERAL LIFE INSURANCE COMPANY

RETURN OF PURCHASE PAYMENT

[OPTIONAL] DEATH BENEFIT ENDORSEMENT

This Endorsement is a part of the Contract to which it is attached. Should any provision in this
Endorsement conflict with the Contract, the provisions of this Endorsement will prevail.

Capitalized terms within this Endorsement that are not defined in this Endorsement are defined or
otherwise described in the Contract to which this Endorsement is attached, including any
endorsements or other riders attached to such Contract.

This Endorsement replaces the “AMOUNT OF DEATH BENEFIT” and “SPOUSAL BENEFICIARY CONTINUATION”
provisions under the “DEATH PROVISIONS” section in the Contract.

TABLE OF CONTENTS

	 	 	 	 	 

	Definitions
	 	Page 1
	[Endorsement Data Page
	 	Page 1]
	Amount of Death Benefit
	 	Page 2
	Spousal Beneficiary Continuation
	 	Page 2
	[Investment Requirements
	 	Page 2]
	Cancellation of the Return of Purchase Payment [Optional] Death Benefit Endorsement
	 	Page 2

DEFINITIONS

For the purposes of this Endorsement, the following Definition applies:

NET PURCHASE PAYMENT(S)

Net Purchase Payment(s) are the sum of all Purchase Payment(s), reduced for each Withdrawal in the
same
proportion that the Contract Value is reduced by each such Withdrawal.

[ENDORSEMENT DATA PAGE

	 	 	 

	RETURN OF PURCHASE PAYMENT

[OPTIONAL] DEATH BENEFIT CHARGE:

	 	[Prior to Your [76th]
birthday, ]You will be charged an
Annual fee of [0.15%] of the average
daily ending value of the assets
attributable to the Accumulation
Units of the Variable Portfolio(s)
to which Your Contract is allocated.
[On and after Your
[76th] birthday the
Annual fee charge will be [zero].]We
deduct this charge daily. This
charge is in addition to other
charges, fees and expenses described
in Your Contract.]

For Inquiries Call: [1-800-445-7862]

AGE-8027 (5/14)

1

 

AMOUNT OF DEATH BENEFIT

Upon Your death, We will pay a Death Benefit to the Beneficiary upon Our receiving all Required
Documentation.

[[If] You are Age [75] or younger on the Contract Date and] Your death occurs prior to Age [76],]
We will calculate the Death Benefit as the great[er/est] of:

	 	1.	 	The Contract Value on the Business Day during which We receive all Required Documentation;
or
	 
	 	2.	 	Net Purchase Payment(s) received prior to Your [86th] birthday[; or
	 
	 	3.	 	The Contract Value on the [5th] Contract Anniversary plus Purchase
Payments received since such Contract Anniversary and prior to Your [86th]
birthday, reduced proportionately by any Withdrawals after such Contract Anniversary].

[If You are Age [76] or older at the time of death, the amount of the Death Benefit is the Contract
Value on the Business Day during which We receive all Required Documentation.]

SPOUSAL BENEFICIARY CONTINUATION

If the Spousal Beneficiary (“Continuing Spouse”) continues the Contract on the Continuation Date,
We will contribute to the Contract any amount by which the Death Benefit exceeds the Contract
Value, calculated on the Business Day during which We receive all Required Documentation of the
Owner’s death.

If the Spousal Beneficiary was Age [75 or younger] on the Continuation Date, We will calculate the
Death Benefit as the great[er/est] of:

	 	1.	 	The Contract Value on the Business Day during which We receive all Required Documentation;
or
	 
	 	2.	 	The Contract Value on the Continuation Date, plus Purchase Payment(s) received
since the Continuation Date and prior to the Spousal Beneficiary’s [86th]
birthday, reduced proportionately by any Withdrawals after the Continuation Date[; or
	 
	 	3.	 	The Contract Value on the [5th] Contract Anniversary plus Purchase Payments
received since such Contract Anniversary and prior to the Spousal Beneficiary’s
[86th] birthday, reduced proportionately by any Withdrawals after such
Contract Anniversary].

[If the Spousal Beneficiary was Age [76] or older on the Continuation Date [or Age [76] or older at
the time of death], the amount of the Death Benefit is the Contract Value on the Business Day
during which We receive all Required Documentation and the Return of Purchase Payment [Optional]
Death Benefit Charge will no longer be deducted as of the Continuation Date.]

[Investment Requirements

[If You are Age [76] or older on the Contract Date,] We require that You allocate Your Purchase
Payment(s), Spousal Continuation Contribution, if applicable, and Contract Value in accordance with
established requirements stated in the Prospectus. [We require enrollment in a [quarterly]
automatic asset rebalancing program that complies with the investment requirements.] [In addition
to [quarterly] automatic asset rebalancing, We will initiate rebalancing in accordance with Your
most current and compliant automatic asset rebalancing instructions on file after any Withdrawal or
transfer You initiate.]]

AGE-8027 (5/14)

2

 

Cancellation of the Return of Purchase Payment [Optional] Death Benefit Endorsement

You cannot cancel this Endorsement [in the first [5] Contract Years unless You surrender Your
Contract. You may cancel this Endorsement as detailed below. The Return of Purchase Payment Death
Benefit may not be re-elected or reinstated after cancellation. After cancellation, the Return of
Purchase Payment Death Benefit Charge will no longer be deducted].

[Cancellation Effective Date

Following Our receipt of Your Written request for cancellation, Your cancellation request will be
effective as follows:

If it is received:

	 	1.	 	In the first [5] Contract Years, the cancellation is effective on the
[5th] Contract Year Anniversary;
	 
	 	2.	 	In any Contract Year after the [5th] Contract Year Anniversary, the
cancellation is effective [on the Contract Year Anniversary] following Our receipt of
the cancellation request.]

Signed for the Company to be effective on the Contract Date.

	 	 	 

	
	 	

AGE-8027 (5/14)

3exv4we

EXHIBIT (4)(e)

	 	 	 	 	 	 	 

	American General 

Life Insurance Company
	 	 	 	 	 	 
	Address mail to:

	 	Regular Mail
	 	Overnight Mail	 	 
	Annuity Service Center

	 	P.O. Box 15570
	 	1050 North Western Street	 	 
	 

	 	Amarillo, TX 79105-5570
	 	Amarillo, TX 79106-7011
	 	 1-800-445-7862

 

Extended Legacy Program Guide

 

What is the Extended Legacy Program?

The Extended Legacy Program is a death claim settlement program that provides claimants of
variable annuities the opportunity to defer the distribution of claim proceeds while retaining full
discretionary access to them.

 

Extended Legacy Program

There are two options for this program.

Option 1 This option enables the claimant to defer taking a full distribution until December
31st of the year containing the fifth anniversary of the deceased’s death. Any amounts
remaining in the account as of that date will automatically be distributed to the claimant. The
claimant may take discretionary distributions of up to 100% of the current value of the death claim
proceeds at any time during the five year period.

Option 2 This option enables the claimant to receive annual required minimum distributions,
generally over the claimant’s life expectancy, beginning no
later than
December 31st of the
year following the year of the deceased’s death. The claimant may take discretionary distributions
of up to 100% of the current value of the death claim proceeds at any time.

Both options have tax implications that should be considered before making a decision. We recommend
that you discuss your situation with a tax professional.

 

Program Availability

The Extended Legacy Program is available to claimants of American General variable annuities.
One or both options may not be available to certain claimants. Please review the Variable Annuity
Death Claim form (SA2200POS) for additional information. Contact our Annuity Service Center at
(800) 445-7862 for information regarding availability.

 

How Do I Use This Guide?

If you elect the Extended Legacy Program, the product issued to the deceased determines the
applicable fees and investment options available to you.

To review the applicable fees and investment options available to you:

	 	1.	 	Identify the product to which you are a claimant. The product name can be found in the
upper-right corner of the deceased’s last quarterly statement. Contact our Annuity Service Center
if you need assistance.
	 
	 	2.	 	Review the investment options available to you. Refer to the product prospectus you received
with this Guide that lists the investment options available to you. Additional information
regarding the investment options can be found in the fund prospectus available at aig.com/annuities
or through our Annuity Service Center. You will be mailed a copy of the fund prospectus for the
available investment options if you elect the Extended Legacy Program.
	 
	 	3.	 	Write your investment allocation instructions on the Death Claim form. Indicate your investment
allocation instructions on Page 10, Section I, of the Variable Annuity Death Claim form.
	 
	 	4.	 	Review the product prospectus disclosure. The product prospectus you received with this Guide
includes important information about the administrative features available to you. Please review
the sections of the prospectus related to Fee table, Investment Options, Transfers, Dollar Cost
Averaging, Systematic Withdrawal, Automatic Asset Rebalancing Program, Extended Legacy Program,
Separate Account Expenses, Taxes and Other Information.

Variable annuities issued by American General Life Insurance Company.

EXTLEGAA.5 Rev. 11.14EX-10.1

 Exhibit 10.1 

COMMON STOCK AND CONVERTIBLE DEBENTURE 

PURCHASE AGREEMENT 

This Common Stock and Convertible Debenture Purchase Agreement (this “Agreement”) is dated as of
October 29, 2014, between Manitex International, Inc., a Michigan corporation (the “Company”), and Terex Corporation, a Delaware corporation (the “Purchaser”). 

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities
Act (as defined below) and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company certain securities of the Company, as more fully described in this Agreement.

 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable
consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows: 
 ARTICLE 1. 

DEFINITIONS 
 1.1.
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated in this Section 1.1: 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or
more intermediaries, controls or is controlled by or is under common control with such specified Person, as such terms are used in and construed under Rule 144. 

“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or
authorized by applicable law to be closed in New York City. 
 “Closing” means the closing of the purchase
and sale of the Common Shares and Convertible Debenture pursuant to Article II. 
 “Closing Date”
means December 19, 2014, or such other date as the parties may agree. 
 “Commission” means the
Securities and Exchange Commission. 
 “Common Shares” means the shares of Common Stock issued or issuable
to the Purchaser pursuant to this Agreement. 
 “Common Stock” means the common stock of the Company, no
par value per share. 
 “Common Stock Investment Amount” means $12,500,000. 

  

 “Common Stock Per Share Purchase Price” equals the average of
the daily volume weighted average price per share of Common Stock on the NASDAQ Capital Market for the period of thirty consecutive Trading Days ending on the second full Trading Day prior to the date of this Agreement; provided, however, the
parties agree to recalculate the Common Stock Per Share Purchase Price as of the second full Trading Day prior to Closing and such recalculated Common Stock Per Share Purchase Price shall be used for purposes of the calculation in
Section 2.2(a); provided, further, however, in no event shall such recalculated Common Stock Per Share Purchase Price be less than 90% or more than 110% of the original Common Stock Per Share Purchase Price. 

“Company SEC Reports” shall have the meaning set forth in Paragraph 3.1(g). 

“Convertible Debenture” means the Subordinated Convertible Debenture in aggregate principal amount of
$7,500,000 bearing the terms set forth in the term sheet attached hereto as Exhibit A. 
 “Convertible
Debenture Investment Amount” means $7,500,000. 
 “Exchange Act” means the Securities Exchange Act
of 1934, as amended. 
 “Investment Amount” means the sum of the Common Stock Investment Amount and the
Convertible Debenture Investment Amount. 
 “Lien” means any lien, charge, encumbrance, security interest,
pledge, mortgage, right of first refusal or other restrictions of any kind. 
 “Material Adverse Effect”
means any of (i) a material and adverse effect on the legality, validity or enforceability of this Agreement, or (ii) a material and adverse effect on the results of operations, assets, prospects, business or condition (financial or
otherwise) of the Company. 
 “Person” means an individual or corporation, partnership, trust, incorporated
or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Trading Day” means a day on which the Common Stock is traded on The NASDAQ Capital Market, provided, that in
the event that the Common Stock is not listed for trading on the NASDAQ Capital Market after the date hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, the American Stock Exchange, the NASDAQ
Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or OTC Bulletin Board on which the Common Shares are listed or quoted for trading on the date in question. 

  
 2 

 ARTICLE 2. 

PURCHASE AND SALE 

2.1. Closing. Subject to the terms and conditions set forth in this Agreement, at the Closing the Company shall issue
and sell to the Purchaser, and the Purchaser shall purchase from the Company, the Common Shares and the Convertible Debenture. The Closing shall take place on the Closing Date at such location as the parties may agree. 

2.2. Closing Deliveries. 

(i) (a) At the Closing, the Company shall deliver or cause to be delivered to the Purchaser (i) a certificate evidencing
a number of Common Shares equal to the Purchaser’s Common Stock Investment Amount divided by the Common Stock Per Share Purchase Price, registered in the name of the Purchaser, and (ii) the executed Convertible Debenture registered in the
name of the Purchaser. 
 (b) At the Closing, the Purchaser shall deliver or cause to be delivered to the Company the
Investment Amount, in United States dollars and in immediately available funds, by wire transfer to an account designated in writing by the Company for such purpose. 

2.3. Closing Conditions. 

(a) The obligation hereunder of the Company to issue and sell the Common Shares and the Convertible Debenture to the Purchaser
at the Closing Date is subject to the satisfaction or waiver, at or before the Closing of the following conditions: 

(i) The representations and warranties of the Purchaser shall be true and correct in all material respects as
of the date when made and as of the Closing Date; 
 (ii) The Purchaser shall have performed, satisfied and
complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date; 

(iii) On the Closing Date, the Purchaser shall have delivered to the Company a certificate signed by an
executive officer on behalf of the Purchaser, dated as of the Closing Date, confirming on behalf of the Purchaser the conditions precedent set forth in paragraphs (i) and (ii) of this Section 2.3(a) as of the Closing Date; and 

(iv) The Investment Amount shall have been delivered to the Company on the Closing Date. 

(b) The obligation hereunder of the Purchaser to purchase the Common Shares and the Convertible Debenture from the Company at
the Closing Date is subject to the satisfaction or waiver, at or before the Closing of the following conditions: 

  
 3 

 (i) The representations and warranties of the Company shall be
true and correct in all material respects as of the date when made and as of the Closing Date; 
 (ii) The
Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date; 

(iii) On the Closing Date, the Company shall have delivered to the Purchaser a certificate signed by an
executive officer on behalf of the Company, dated as of the Closing Date, confirming on behalf of the Company the conditions precedent set forth in paragraphs (i) and (ii) of this Section 2.3(b) as of the Closing Date; 

(iv) No judgment, order, injunction, decree, statute, law, ordinance, rule or regulation, or other legal
restraint or prohibition (whether temporary, preliminary or permanent), entered, enacted, promulgated, enforced or issued by any court or other governmental authority of competent jurisdiction shall be in effect that prohibits, makes illegal or
enjoins the consummation of the transactions contemplated hereby; and 
 (v) The Common Stock and Common
Shares into which the Convertible Debenture is convertible shall be approved for listing by the NASDAQ Capital Market. 
 ARTICLE 3. 

REPRESENTATIONS AND WARRANTIES 

3.1. Representations and Warranties of the Company. The Company hereby makes the following representations and
warranties to the Purchaser: 
 (a) Organization and Qualification. The Company is duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite power and authority to own and use its properties and assets and to carry on its business as
currently conducted. The Company is not in violation of any of the provisions of its certificate of incorporation, bylaws or other organizational or charter documents. The Company is duly qualified to conduct its business and is in good standing as
a foreign corporation or other entity (as applicable) in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except for such jurisdictions where the failure to be so qualified
or in good standing, as the case may be, would not have a Material Adverse Effect. 
 (b) Authorization; Enforcement.
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the
Company and the consummation by it of the transactions contemplated thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company in connection therewith. This Agreement has
been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its
terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other
equitable principles of general application. 

  
 4 

 (c) Non-Contravention; Consents. 

(i) The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions
contemplated hereby and thereby, do not and will not (A) violate any provision of the certificate or articles of incorporation, bylaws or comparable organizational documents of the Company thereof; (B) conflict with, result in a breach of,
constitute a default under, result in the termination, cancellation or acceleration with respect to, any term or provision of any contract, commitment, right or other obligation to which the Company or any of its Affiliates is a party or is subject;
or (C) violate or result in a breach of or constitute a default under any law or other restriction of any governmental authority to which the Company is subject, except with respect to clauses (B) and (C), for violations, breaches,
conflicts, defaults, terminations, cancellations or accelerations as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

(ii) The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby
do not require any consent, authorization or approval from any third party or any governmental authority on the part of the Company or its Affiliates. 

(d) No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the
Company of the transactions contemplated thereby do not and will not result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court, regulatory body, administrative agency, governmental
authority or other authority to which the Company is subject (including federal and state securities laws and regulations). 

(e) Capitalization. 

(i) As of the date of this Agreement, the authorized capital stock of the Company consisted of 20,000,000 shares of the
Common Stock, of which there were 13,822,918 shares issued and outstanding as of September 30, 3014, and 150,000 Preferred Shares, par value $0.01 per share, of which there are zero shares issued or outstanding. All outstanding shares of the
Common Stock and Preferred Shares issued and outstanding as of the date of this Agreement are duly authorized and validly issued and are fully paid and non-assessable. 

(ii) The aggregate number of shares of the Common Stock reserved for issuance under the Company’s stock option and
equity incentive plans, is as specified in the Company SEC Reports as of the respective dates specified therein. No holders of securities of the Company are entitled to preemptive or similar rights, and no Person has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement. The issue and sale of the Common Shares will not obligate the Company to issue shares of the Company Stock or other
securities to any Person (other than Purchaser) and will not result in a right of any holder of the Company securities to 

  
 5 

 
adjust the exercise, conversion, exchange or reset price under any option, right or warrant to acquire (or any similar instrument), or any securities convertible into or exchangeable for, the
Company Stock. 
 (f) Issuance of the Common Shares and Convertible Debenture. The Common Shares and Convertible
Debenture have been duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and non-assessable and free and clear of all Liens. The Company has reserved from its duly authorized
capital stock the shares of Common Stock issuable pursuant to this Agreement in order to issue the Common Shares and the Convertible Debenture. 

(g) Company SEC Reports; Financial Statements. 

(i) The Company has filed or furnished all forms, reports and documents required to be filed or furnished by the Company with
the Company on a timely basis or has timely filed a valid extension of such time of filing and has filed any such the Company SEC Reports prior to the expiration of any such extension. All such required forms, reports and documents (including those
that the Company may file subsequent to the date hereof) are referred to herein as the “Company SEC Reports”. As of the time of their respective filing or furnishing (or if amended or superseded by a later filing prior to the date
hereof, then on the date of later such filing), the Company SEC Reports (i) were or will be prepared in accordance with and complied or will comply with the requirements of the Securities Act or the Exchange Act, as the case may be, and the
rules and regulations of the Company thereunder applicable to such the Company SEC Reports, and (ii) did not or will not (or if amended or superseded by a later filing prior to the date hereof, then on the date of such later filing) contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made not misleading. 

(ii) Each of the consolidated financial statements (including, in each case, any related notes thereto) contained in any of
the Company SEC Reports (the “Company Financials”), (a) complied or will comply in all material respects with the published rules and regulations of the Company with respect thereto, (b) was or will be prepared in
accordance with U.S. GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited interim financial statements, as may be permitted by the Company on
Forms 10-Q, 8-K or any successor form under the Exchange Act) and conform with applicable requirements of Regulation S-X in all material respects and (c) fairly presents or will fairly present in all material respects the consolidated
financial position of the Company and its Subsidiaries as at the respective dates thereof and the consolidated results of the Company’s operations and cash flows for the periods indicated, except that the unaudited interim financial statements
may contain condensed footnotes in accordance with Article 10 of Regulation S-X and were or are subject to recurring year-end adjustments. 

(iii) Since June 30, 2014, there has not been a Material Adverse Effect. 

(iv) The Company maintains a system of internal accounting and financial controls sufficient to provide reasonable assurances
that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP in all material respects. 

  
 6 

 (h) Certain Registration Matters. Assuming the accuracy of the
Purchaser’s representations and warranties set forth in Section 3.2(b)-(e), no registration under the Securities Act is required for the offer and sale of the Common Shares and the Convertible Debenture by the Company to the Purchaser
under this Agreement. The Company has not granted or agreed to grant to any Person any rights (including “piggy-back” registration rights) to have any of its securities registered with the Company or
any other governmental authority that have not been satisfied. 
 (i) Listing Compliance. The Company is in
compliance in all respects with the requirements for continued listing of the Common Stock on the Trading Market on which the Common Stock is currently listed. The issuance and sale of the Common Stock to the Purchaser under this Agreement
(including any Common Shares into which the Convertible Debenture is convertible) does not contravene the rules and regulations of the Trading Market on which the Common Stock is currently listed, and no approval of the stockholders of the Company
thereunder is required for the Company to issue and deliver to the Purchaser the Common Stock or the Convertible Debenture contemplated by this Agreement. 

3.2. Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company as
follows: 
 (a) Authority. The Purchaser has the requisite legal capacity to enter into and to consummate the
transactions contemplated by this Agreement and otherwise to carry out its obligations thereunder. This Agreement has been (or upon delivery will have been) duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the
terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. 

(b) Non-Contravention; Consents. (i) The execution, delivery and performance by the Purchaser of this Agreement
and the consummation of the transactions contemplated hereby and thereby, do not and will not (A) violate any provision of the certificate or articles of incorporation, bylaws or comparable organizational documents of the Purchaser thereof;
(B) conflict with, result in a breach of, constitute a default under, result in the termination, cancellation or acceleration with respect to, any term or provision of any contract, commitment, right or other obligation to which the Company or
any of its Affiliates is a party or is subject; or (C) violate or result in a breach of or constitute a default under any law or other restriction of any governmental authority to which the Purchaser is subject, except with respect to clauses
(B) and (C), for violations, breaches, conflicts, defaults, terminations, cancellations or accelerations as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

  
 7 

 (ii) The execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby do not require any consent, authorization or approval from any third party or any governmental authority on the part of the Purchaser or its Affiliates. 

(c) No Conflicts. The execution, delivery and performance of this Agreement by the Purchaser and the consummation by
the Purchaser of the transactions contemplated thereby do not and will not result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court, regulatory body, administrative agency,
governmental authority or other authority to which the Purchaser is subject (including federal and state securities laws and regulations). 

(d) Investment Intent. The Purchaser is acquiring the Common Shares and Convertible Debenture as principal for its own
account for investment purposes only and not with a view to or for distributing or reselling such Shares or any part thereof, without prejudice, however, to the Purchaser’s right at all times to sell or otherwise dispose of all or any part of
such Shares in compliance with applicable federal and state securities laws. The Purchaser does not have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Common Shares and Convertible Debenture. 

(e) Purchaser Status. At the time the Purchaser was offered the Common Shares and Convertible Debenture, it was, and at
the date hereof it is, an “accredited Purchaser” as defined in Rule 501(a) under the Securities Act. The Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act. 

(f) General Solicitation. The Purchaser is not purchasing the Common Shares and Convertible Debenture as a result of
any advertisement, article, notice or other communication regarding the Common Shares and Convertible Debenture published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other
general solicitation or general advertisement. 
 (g) Independent Investment Decision. The Purchaser has
independently evaluated the merits of its decision to purchase Shares pursuant to this Agreement, and the Purchaser confirms that it has not relied on the advice of the Company’s business advisors and/or legal counsel in making such decision.

 (h) Investment Amount. The Investment Amount shall be delivered to the Company, free and clear of all Liens. 

ARTICLE 4. 
 OTHER AGREEMENTS OF
THE PARTIES 
 4.1. (a) Shares may only be disposed of in compliance with state and federal securities laws. In connection
with any transfer of the Common Shares and Convertible Debenture other than pursuant to an effective registration statement, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor,
the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares under the Securities Act. 

  
 8 

 (b) Certificates evidencing the Common Shares and Convertible Debenture will bear
the following legend, until such time as they are not required under Section 4.1(c): 
 THE SECURITIES EVIDENCED BY THIS
CERTIFICATE ARE “RESTRICTED SECURITIES” AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES
LAWS COVERING SUCH SECURITIES OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT. 

(c) Certificates evidencing Shares shall not contain any legend (including the legend set forth in Section 4.1(b)):
(i) following a sale, transfer or other disposition of such Shares pursuant to an effective registration statement (including a Registration Statement), or (ii) following a sale or transfer of such Shares pursuant to Rule 144 (assuming the
transferee is not an Affiliate of the Company), (iii) while such Shares are eligible for sale or transfer under Rule 144(k), or (iv) if the transferor provides to the Company an opinion of counsel selected by the transferor, the form and
substance of which opinion shall be reasonably satisfactory to the Company, to the effect that no legend is required for purposes of the Securities Act. 

(d) Furnishing of Information. As long as the Purchaser owns the Common Shares and Convertible Debenture, the Company
covenants to use all commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange
Act. 
 (e) Material Non-Public Information. The Purchaser hereby acknowledges that it is aware that the United States
securities laws prohibit any person who has material non-public information with respect to a public company from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in
which it is reasonably foreseeable that such person is likely to purchase or sell such securities. 
 (f) Listing of the
Common Stock. The Company agrees (i) it will take all action necessary to list the Common Stock and the Common Shares into which the Convertible Debenture is convertible on the applicable Trading Market and to continue the listing and trading
of its Company Shares (and the Common Stock) on a Trading Market and (ii) if required, prior to Closing the Company will submit an Additional Listing Application with the NASDAQ Capital Market with respect to the issuance of the Common Shares.
If the Company applies to have its Common Shares traded on any other Trading Market, it will include in such application the Common Stock issued to the Purchaser and the Common Shares into which the Convertible Debenture is convertible, and will use
commercially reasonable efforts to cause the Common Stock issued to the Purchaser and the Common Shares into which the Convertible Debenture is convertible to be listed on such other Trading Market contemporaneously with the listing of the Common
Shares, or as promptly thereafter as practicable. 

  
 9 

 (g) Conduct of Business Prior to the Closing. 

(i) During the period from and after the date of this Agreement and until the earlier of (x) the
termination of this Agreement or (y) the close of business local time on the Closing Date, the Company agrees that it shall not (A) adjust, split, combine, subdivide, or reclassify the Common Shares or take any other action that could have
a similar effect on the Common Shares, (B) pay any stock dividend in respect of any shares of its capital stock, (C) materially modify or amend the Company’s certificate of incorporation or by-laws, except as required by Law or
required to effectuate the transactions contemplated by this Agreement, or (D) authorize any of, or commit to do or enter into any, binding contract, agreement or arrangement with respect to any of the foregoing actions in clauses
(A) through (C) of this Paragraph. 
 (ii) In the event of a merger or consolidation of the
Company into another company prior to the Closing as a result of which the outstanding the Company Shares is converted into or exchanged for securities and/or other property or assets of the surviving corporation the Purchaser, rather than being
entitled to the Common Shares and the Convertible Debenture, will be entitled to receive at the Closing the kind and amount of securities and/or other property or assets of the surviving corporation that the Purchaser would have received in respect
of the Common Stock and the Convertible Debenture had it acquired the Common Stock and the Convertible Debenture immediately prior to the record date for determining the holders of the Company Shares and Convertible Debenture entitled to receive
such securities and/or other property or assets in respect of such merger or consolidation. 
 (h) Expenses. Whether
or not the Closing takes place, and except as otherwise specified in this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such expense. The
Company shall pay any filing fees or similar charges with respect to any governmental approval. 
 (i) Further
Assurances. Each party shall use all commercially reasonable efforts to take, or cause to be taken, all appropriate action, do or cause to be done all things necessary, proper or advisable under applicable Law, and execute and delivery such
documents and other papers, as reasonably requested by the other party and necessary to consummate the transactions contemplated by this Agreement, including, but not limited to, satisfying the agreements and conditions set forth under this
Agreement. 
 ARTICLE 5. 

MISCELLANEOUS 

5.1. Fees and Expenses. The Company shall pay all costs and expenses incurred by it or on its behalf, and the Purchaser
shall pay all costs and expenses incurred by it or on its behalf in connection with this Agreement, including without limitation the fees and expenses of its financial consultants, accountants and counsel. 

  
 10 

 5.2. Entire Agreement. This Agreement contains the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules. 
 5.3. Notices. Any notice required or permitted to be given under this Agreement
by any party shall be in writing and shall be sufficiently given if delivered personally, by prepaid overnight courier or by telefacsimile tested prior to transmission: 

in the case of a notice to Seller, at: 

Terex Corporation 

200 Nyala Farm Road 

Westport, CT 06880 

Attention: Eric I Cohen, Esq. 

Telephone: (203) 222-5950 

Fax: (203) 722-7766 

in the case of a notice to Buyer: 

Manitex International, Inc. 

9725 Industrial Drive 

Bridgeview, Illinois 60455 

Facsimile: (708) 430-1335 

Attention: Andrew Rooke 

Telephone: (708) 237-2056 

Fax: (708) 430-1335 

with a copy to: 

Bryan Cave LLP 

161 N. Clark Street 

Suite 4300 

Chicago, Illinois 60601 

Attention: John P. Goebel, Esq. 

Telephone: (312) 602-5155 

Fax: (312) 698-7555 

or at such other address for a party as shall be specified by like notice. 

  
 11 

 All such notices and other communications shall, when mailed by return receipt requested or
certified mail, or by means of any nationally recognized overnight express company, or telecopied, be effective when delivered to the notice address (as evidenced by any signature for delivery at the notice address) or upon receipt of confirmation
of delivery thereof by telecopier, respectively and such notices or communications shall be effective when delivered at the address in the case of hand delivery. Either party hereto may change its address specified for notices herein by designating
a new address by notice in accordance with this Section 5.3. 
 5.4. Amendments; Waivers; No Additional
Consideration. No provision of this Agreement may be waived or amended except in a written instrument signed by the Company and the Purchaser. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any
manner impair the exercise of any such right. 
 5.5. Construction. The headings herein are for convenience only, do
not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules
of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
provisions of this Agreement. 
 5.6. Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and permitted assigns. No party to this Agreement may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party hereto. 

5.7. No Third-party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their
respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 

5.8. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New
York without regard to its conflict of laws principles. The Parties hereto hereby agree to be subject to the exclusive personal jurisdiction in the federal and state courts of the State of New York located in New York City, New York and any award
which may be enforced in regard to this Agreement may be enforced in such federal and state courts of the State of New York. Each of the Parties hereto hereby agrees to irrevocably and unconditionally waive trial by jury in any judicial proceeding
between or among the Parties arising out of or related to the Transactions. 
 5.9. Survival. The representations,
warranties, agreements and covenants contained herein shall survive the Closing and the delivery of the Common Shares and Convertible Debenture. 

  
 12 

 5.10. Execution. This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need
not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile signature page were an original thereof. 
 5.11. Severability. If any
provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will
attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. 

5.12. Replacement of Shares. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or
destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs
associated with the issuance of such replacement Shares. If a replacement certificate or instrument evidencing any Shares is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a
condition precedent to any issuance of a replacement. 
 5.13. Remedies. In addition to being entitled to exercise
all rights provided herein or granted by law, including recovery of damages, the Purchaser and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary damages may not be adequate compensation for
any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 

[Signature Page to Follow] 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have caused this Common Stock and
Convertible Debenture Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	 MANITEX INTERNATIONAL, INC.

		
	 By:
	 	 /s/ David J. Langevin

		 	 Name: David J. Langevin

		 	 Title: Chairman & CEO

  

			
	 TEREX CORPORATION

		
	 By:
	 	 /s/ Eric I. Cohen

		 	 Name: Eric I. Cohen

		 	 Title: Senior Vice President

  

 EXHIBIT A 

CONVERTIBLE DEBENTURE TERM SHEET 

See attached. 

  

 Preliminary Convertible Debt Term Sheet 

 

			
	 Term
	  	 Description

		
	 Issuer:
	  	 Manitex International, Inc. (the “Company”)

		
	 Offering Size:
	  	 $7,500,000

		
	 Ranking:
	  	 Subordinated

		
	 Maturity:
	  	 6 Years

		
	 Optional Redemption:
	  	 Non-callable for 3 years; thereafter, Issuer may redeem all, but not less than all, of the Notes if the last reported sale price of Issuer’s common
stock equals or exceeds 130% of the applicable conversion price for at least 20 trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date Issuer delivers notice of the redemption

		
	 Coupon:
	  	 5.00% per annum, payable semi-annually

		
	 Conversion Price:
	  	 Initial Conversion Price will be set to the greater of:

(i) 25% above the average closing price for the 30 trading days ending on the Announcement Date

(ii) 10% above the average closing price for the 30 trading days ending on the Closing Date, subject to a maximum conversion price of
$16.75

		
	 Conversion Rights:
	  	 Convertible only if one of the following conditions is satisfied:

(i) Stock trading at 110% of conversion price; or

(ii) Upon occurrence of specific corporate transactions; or

(iii) Last 6 months prior to maturity; or

(iv) Upon receipt of a redemption notice from Issuer

		
	 Conversion Settlement:
	  	 Optional Net Share Settlement; settlement in cash, shares of common stock or a combination of cash and shares at the Issuer’s option

		
	Conversion Rate Adjustments:	  	 Standard anti-dilution adjustments for dividends, stock splits, below market rights / warrants, asset distributions and tender or exchange
offers

		
	Repurchase at Option of Holders upon a Fundamental Change:	  	 Upon a fundamental change, holders may put the notes to the issuer for par plus accrued interest

A “fundamental change” is a change of control or a termination of trading

A “change of control” occurs upon:
  

i.       50% vote change; or

 

ii.      Merger (excluding merger solely to re-domicile issuer or where
consideration is 100% common stock); or
  

iii.    Liquidation or dissolution

 

iv.     If continuing directors cease to be a majority of the Board

 
 A “termination of trading” occurs upon a delisting
from U.S. exchange or U.S. OTC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]